While prior studies have linked CD73 expression to EGFR‐driven signaling and poor prognosis in cancer patients,[44, 45, 46] our findings delineate the precise molecular mechanism underlying CD73 upregulation in EGFR‐mutant NSCLC and confirming its pivotal role in shaping an immunosuppressive TME. This evidence concerns the gene EGFR and cancer.